Showing results (941-950 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|September 17, 2009
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumorsLokesh Jain, Craig A Vargo, Romano Danesi, et al.
Molecular Cancer Therapeutics|September 17, 2009
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patientsWindy Berkofsky-Fessler, Tri Q Nguyen, Paul Delmar, et al.
Molecular Cancer Therapeutics|September 17, 2009
Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin-inducer peptidesMichel Obeid
Molecular Cancer Therapeutics|August 13, 2009
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutationsIssan Yee-San Tam, Elaine Lai-Han Leung, Vicky Pui-Chi Tin, et al.
Molecular Cancer Therapeutics|August 13, 2009
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumorLori Rink, Yuliya Skorobogatko, Andrew V Kossenkov, et al.
Molecular Cancer Therapeutics|August 13, 2009
Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasisClaudia Binder, Thorsten Hagemann, Swetlana Sperling, et al.
Molecular Cancer Therapeutics|August 13, 2009
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate modelJill K Slack-Davis, E Daniel Hershey, Dan Theodorescu, et al.
Molecular Cancer Therapeutics|August 13, 2009
Enhanced targeting with heterobivalent ligandsLiping Xu, Josef Vagner, Jatinder Josan, et al.
Molecular Cancer Therapeutics|August 13, 2009
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activityTerzah M Horton, Gaye Jenkins, Debananda Pati, et al.
Molecular Cancer Therapeutics|August 13, 2009
Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cellsBrian J Albert, Peter A McPherson, Kristine O'Brien, et al.
Pageof 599